MedDataX Logo

Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care

NCT ID: NCT01105325

Last Updated: 2010-10-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-04-30

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study compliance with secondary prevention during the first months following discharge from the cardiac intensive care unit (CIC) of patients experiencing a first episode of acute coronary syndrome : quantitative compliance over 3 months with the two principal treatments of the prescription (a statin - rosuvastatin, Crestor® and a platelet aggregation inhibitor - clopidogrel, Plavix®), using an electronic measure system ("intelligent blister" pack®);

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient admitted to the CIC unit for a first episode of acute coronary syndrome, in whom the CIC cardiologist considers that Crestor® -rosuvastatin is the most appropriate statin, in combination with a platelet aggregation inhibitor (Plavix®-clopidogrel)
* Patient giving his/her oral consent to participate in the study.
* Patient not previously treated by a lipid-lowering drug.

Exclusion Criteria

* Patient with a known history of coronary heart disease.
* Patient whose treatment on discharge comprises only one of the two study treatments
* Patient participating or who has participated in the previous 3 months in a biomedical research study in cardiology.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pascal Piedbois

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Antony, , France

Site Status

Research Site

Argenteuil, , France

Site Status

Research Site

Arras, , France

Site Status

Research Site

Avignon, , France

Site Status

Research Site

Bayonne, , France

Site Status

Research Site

Boulogne-Billancourt, , France

Site Status

Research Site

Bourges, , France

Site Status

Research Site

Caen, , France

Site Status

Research Site

Cholet, , France

Site Status

Research Site

Clamart, , France

Site Status

Research Site

Colmar, , France

Site Status

Research Site

Creil, , France

Site Status

Research Site

Dijon, , France

Site Status

Research Site

Eaubonne, , France

Site Status

Research Site

Épernay, , France

Site Status

Research Site

La Rochelle, , France

Site Status

Research Site

La Tronche, , France

Site Status

Research Site

Le Chesnay, , France

Site Status

Research Site

Le Coudray, , France

Site Status

Research Site

Le Plessis-Robinson, , France

Site Status

Research Site

Lens, , France

Site Status

Research Site

Libourne, , France

Site Status

Research Site

Lomme, , France

Site Status

Research Site

Lorient, , France

Site Status

Research Site

Lyon, , France

Site Status

Research Site

Mantes-la-Jolie, , France

Site Status

Research Site

Marseille, , France

Site Status

Research Site

Metz, , France

Site Status

Research Site

Montfermeil, , France

Site Status

Research Site

Neuilly-sur-Seine, , France

Site Status

Research Site

Nevers, , France

Site Status

Research Site

Niort, , France

Site Status

Research Site

Orléans, , France

Site Status

Research Site

Paris, , France

Site Status

Research Site

Pau, , France

Site Status

Research Site

Perpignan, , France

Site Status

Research Site

Pessac, , France

Site Status

Research Site

Périgueux, , France

Site Status

Research Site

Reims, , France

Site Status

Research Site

Rodez, , France

Site Status

Research Site

Saint-Nazaire, , France

Site Status

Research Site

Salouël, , France

Site Status

Research Site

Schiltigheim, , France

Site Status

Research Site

Strasbourg, , France

Site Status

Research Site

Toulouse, , France

Site Status

Research Site

Troyes, , France

Site Status

Research Site

Valence, , France

Site Status

Research Site

Vandœuvre-lès-Nancy, , France

Site Status

Research Site

Villeneuve-Saint-Georges, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-CFR-CRE-2010/1

Identifier Type: -

Identifier Source: org_study_id